MindMed to Present at Upcoming May Medical Conferences
25 Abril 2024 - 6:00AM
Business Wire
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the
“Company” or “MindMed”), a clinical stage biopharmaceutical company
developing novel product candidates to treat brain health
disorders, announced today that it will present detailed results
from its phase 2b study of MM120 in Generalized Anxiety Disorder
(GAD), as well as multiple presentations describing the
epidemiology and growing burden of GAD at two upcoming medical
conferences:
American Psychiatric Association (APA)
2024 Congress, New York, NY Title: Rapid and
Durable Response to a Single Dose of MM120 (Lysergide) in
Generalized Anxiety Disorder: A Dose-Optimization Study
Format: Poster Presenter: Dan Karlin, MD Date:
Saturday, May 4, 2024
Title: Screening Adults in the US General Population
to Detect Cases of Undiagnosed Generalized Anxiety Disorder
Format: Poster Presenter: Phong Duong, PharmD
Date: Saturday, May 4, 2024
Title: Quantifying the Burden of Undiagnosed
Generalized Anxiety Disorder in the US General Adult Population
Format: Poster Presenter: Phong Duong, PharmD
Date: Saturday, May 4, 2024
International Society for
Pharmacoeconomics and Outcomes Research (ISPOR) 2024, Atlanta,
GA Title: Health-related Quality of Life Among
Adults Diagnosed with Generalized Anxiety Disorder in the United
States Format: Poster Presenter: Phong Duong,
PharmD Date: Monday, May 6, 2024
Title: Health Care Resource Use Associated with
Undiagnosed and Diagnosed Generalized Anxiety Disorder Among Adults
in the United States Format: Poster Presenter:
Phong Duong, PharmD Date: Monday, May 6, 2024
Title: Work Productivity Loss and Activity Impairment
among Adults Diagnosed with Generalized Anxiety Disorder in the
United States Format: Poster Presenter: Phong
Duong, PharmD Date: Wednesday, May 8, 2024
Posters will be available on MindMed’s Company website following
the conferences.
About MindMed
MindMed is a clinical stage biopharmaceutical company developing
novel product candidates to treat brain health disorders. Our
mission is to be the global leader in the development and delivery
of treatments that unlock new opportunities to improve patient
outcomes. We are developing a pipeline of innovative product
candidates, with and without acute perceptual effects, targeting
neurotransmitter pathways that play key roles in brain health
disorders. MindMed’s common shares trade on Nasdaq under the symbol
MNMD.
Forward-Looking Statements
Certain statements in this news release related to the Company
constitute “forward-looking information” within the meaning of
applicable securities laws and are prospective in nature.
Forward-looking information is not based on historical facts, but
rather on current expectations and projections about future events
and are therefore subject to risks and uncertainties which could
cause actual results to differ materially from the future results
expressed or implied by the forward-looking statements. These
statements generally can be identified by the use of
forward-looking words such as “will”, “may”, “should”, “could”,
“intend”, “estimate”, “plan”, “anticipate”, “expect”, “believe”,
“potential” or “continue”, or the negative thereof or similar
variations. Forward-looking information in this news release
includes, but is not limited to, statements regarding anticipated
upcoming presentations; and the potential benefits of the Company’s
product candidates. There are numerous risks and uncertainties that
could cause actual results and the Company’s plans and objectives
to differ materially from those expressed in the forward-looking
information, including history of negative cash flows; limited
operating history; incurrence of future losses; availability of
additional capital; lack of product revenue; compliance with laws
and regulations; difficulty associated with research and
development; risks associated with clinical trials or studies;
heightened regulatory scrutiny; early stage product development;
clinical trial risks; regulatory approval processes; novelty of the
psychedelic inspired medicines industry; as well as those risk
factors discussed or referred to herein and the risks described in
the Company’s Annual Report on Form 10-K for the fiscal year ended
December 31, 2023, under headings such as “Special Note Regarding
Forward-Looking Statements,” “Risk Factors” and “Management’s
Discussion and Analysis of Financial Condition and Results of
Operations,” and other filings and furnishings made by the Company
with the securities regulatory authorities in all provinces and
territories of Canada which are available under the Company’s
profile on SEDAR+ at www.sedarplus.ca and with the U.S. Securities
and Exchange Commission on EDGAR at www.sec.gov. Except as required
by law, the Company undertakes no duty or obligation to update any
forward-looking statements contained in this release as a result of
new information, future events, changes in expectations or
otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240425701302/en/
For Media: media@mindmed.co For Investors:
ir@mindmed.co
Mind Medicine MindMed (NASDAQ:MNMD)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Mind Medicine MindMed (NASDAQ:MNMD)
Gráfica de Acción Histórica
De May 2023 a May 2024